MCID: HRT032
MIFTS: 76

Heart Disease

Categories: Cardiovascular diseases, Genetic diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Heart Disease

MalaCards integrated aliases for Heart Disease:

Name: Heart Disease 12 6 3 15 17
Congenital Heart Disease 12 30 56 6 15 17 74
Congenital Heart Defects 12 30 6 44 3 15 64
Heart Diseases 45 74
Congenital Anomaly of Heart 12
Disease, Heart, Congenital 41
Congenital Heart Disorder 77
Heart Defects, Congenital 45
Heart Disease, Congenital 41
Congestive Heart Failure 74
Heart Defects Congenital 56
Congenital Heart Defect 12
Heart-Congenital Defect 12
Heart Malformation 12
Heart Failure 74
Heart Defect 12

Classifications:



Summaries for Heart Disease

MedlinePlus : 44 A congenital heart defect is a problem with the structure of the heart. It is present at birth. Congenital heart defects are the most common type of birth defect. The defects can involve the walls of the heart, the valves of the heart, and the arteries and veins near the heart. They can disrupt the normal flow of blood through the heart. The blood flow can slow down, go in the wrong direction or to the wrong place, or be blocked completely. Doctors use a physical exam and special heart tests to diagnose congenital heart defects. They often find severe defects during pregnancy or soon after birth. Signs and symptoms of severe defects in newborns include Rapid breathing Cyanosis - a bluish tint to the skin, lips, and fingernails Fatigue Poor blood circulation Many congenital heart defects cause few or no signs and symptoms. They are often not diagnosed until children are older. Many children with congenital heart defects don't need treatment, but others do. Treatment can include medicines, catheter procedures, surgery, and heart transplants. The treatment depends on the type of the defect, how severe it is, and a child's age, size, and general health. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Heart Disease, also known as congenital heart disease, is related to heart, malformation of and congestive heart failure, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Heart Disease is GATA4 (GATA Binding Protein 4), and among its related pathways/superpathways are Cardiac conduction and Human Embryonic Stem Cell Pluripotency. The drugs Ranolazine and Alprostadil have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are cardiovascular system and muscle

Disease Ontology : 12 A cardiovascular system disease that involves the heart.

CDC : 3 Learn 6 ways moms can take care of their heart health before, during, and after pregnancy.

PubMed Health : 64 About congenital heart defects: Congenital (kon-JEN-ih-tal) heart defects are problems with the heart's structure that are present at birth. These defects can involve:

Wikipedia : 77 A congenital heart defect (CHD), also known as a congenital heart anomaly or congenital heart disease,... more...

Related Diseases for Heart Disease

Diseases in the Heart Disease family:

Congenital Heart Defects, Multiple Types, 6 Congenital Heart Defects, Multiple Types, 3
Congenital Heart Defects, Multiple Types, 2 Congenital Heart Defects, Multiple Types, 4
Congenital Heart Defects, Multiple Types, 5

Diseases related to Heart Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1512)
# Related Disease Score Top Affiliating Genes
1 heart, malformation of 34.2 MYH6 TBX5
2 congestive heart failure 33.5 HOTAIR MYH6 NPPA NPPB
3 cardiac arrest 32.8 NPPB RYR2 SCN5A
4 aortic valve disease 1 32.7 H19 NKX2-5 NPPB
5 patent ductus arteriosus 1 32.6 GATA4 NKX2-5 NPPB
6 hypoplastic left heart syndrome 32.6 MYH6 NKX2-5 NPPA NPPB
7 syncope 32.6 NPPA NPPB SCN5A
8 double outlet right ventricle 32.5 GATA4 NKX2-5 ZIC3
9 familial progressive cardiac conduction defect 32.5 NKX2-5 SCN5A
10 atrial standstill 1 32.1 MIR320A MYH6 NPPB SCN5A
11 dilated cardiomyopathy 32.0 GATA4 MIR196A2 MYH6 NKX2-5 NPPA NPPB
12 atrioventricular block 32.0 GATA4 NKX2-5 NPPB SCN5A TBX5
13 atrial fibrillation 31.9 NPPA NPPB RYR2 SCN5A TBX5
14 aortic valve disease 2 31.8 NPPA NPPB TBX5
15 tricuspid valve disease 31.8 NKX2-5 NPPB ZIC3
16 left ventricular noncompaction 31.6 MYH6 NKX2-5 RYR2 SCN5A
17 third-degree atrioventricular block 31.5 NPPB SCN5A
18 atrial standstill 31.4 NPPA SCN5A
19 atrial heart septal defect 31.4 GATA4 MYH6 NKX2-5 TBX5
20 tetralogy of fallot 31.4 GATA4 MKKS NKX2-5 NPPA NPPB TBX5
21 patent foramen ovale 31.3 GATA4 MYH6 NKX2-5 TBX5
22 ventricular fibrillation, paroxysmal familial, 1 31.3 NKX2-5 RYR2 SCN5A
23 mitral valve insufficiency 31.1 NPPA NPPB TBX5
24 ventricular septal defect 31.0 GATA4 NKX2-5 NPPB TBX5 ZIC3
25 transposition of the great arteries 30.9 NKX2-5 ZIC3
26 atrioventricular septal defect 30.8 GATA4 NKX2-5 TBX5
27 pulmonary valve stenosis 30.8 GATA4 SCN5A
28 familial sick sinus syndrome 30.7 MYH6 SCN5A
29 pulmonary valve disease 30.7 GATA4 TBX5
30 ebstein anomaly 30.5 GATA4 NKX2-5 NPPB
31 holt-oram syndrome 30.5 MYH6 NKX2-5 TBX5
32 central sleep apnea 30.4 NPPA NPPB
33 heart septal defect 30.3 GATA4 NKX2-5 TBX5
34 leukemia, acute myeloid 29.1 ABL1 HOTAIR MIR210 MIR320A
35 deafness, congenital heart defects, and posterior embryotoxon 12.6
36 coronary heart disease 1 12.6
37 short stature, developmental delay, and congenital heart defects 12.6
38 congenital heart defects, dysmorphic facial features, and intellectual developmental disorder 12.5
39 congenital heart defects and ectodermal dysplasia 12.5
40 multiple joint dislocations, short stature, and craniofacial dysmorphism with or without congenital heart defects 12.5
41 hypertensive heart disease 12.5
42 congenital heart defects, multiple types, 3 12.5
43 congenital heart defects, multiple types, 4 12.5
44 rheumatic heart disease 12.4
45 congenital heart defects, hamartomas of tongue, and polysyndactyly 12.4
46 ischemic heart disease 12.4
47 coronary heart disease 6 12.4
48 structural heart defects and renal anomalies syndrome 12.3
49 coronary heart disease 5 12.3
50 critical congenital heart disease 12.3

Comorbidity relations with Heart Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 315)


3-Hydroxyacyl-Coa Dehydrogenase Deficiency Accessory Nerve Disease
Acquired Polycythemia Acquired Thrombocytopenia
Active Peptic Ulcer Disease Acute Anterolateral Myocardial Infarction
Acute Apical Periodontitis Acute Conjunctivitis
Acute Cor Pulmonale Acute Cystitis
Acute Inferolateral Myocardial Infarction Acute Kidney Failure
Acute Maxillary Sinusitis Acute Myocardial Infarction
Acute Myocarditis Acute Pancreatitis
Acute Vascular Insufficiency of Intestine Adjustment Disorder
Age-Related Hearing Loss Alcoholic Cardiomyopathy
Alcoholic Liver Cirrhosis Allergic Urticaria
Alzheimer Disease Amyloidosis
Anemia, Autoimmune Hemolytic Anthracosis
Anxiety Aortic Aneurysm
Aortic Atherosclerosis Aortic Valve Disease 1
Aortic Valve Disease 2 Aortic Valve Insufficiency
Asbestosis Aspergillosis
Asthma Atrial Standstill 1
Atrioventricular Block Atrophic Gastritis
Bacteremia 2 Balanoposthitis
Basilar Artery Insufficiency Benign Essential Hypertension
Benign Hypertensive Renal Disease Benign Renovascular Hypertension
Bleeding Disorder, Platelet-Type, 11 Blepharitis
Blepharoconjunctivitis Bronchiectasis
Bronchitis Bronchopneumonia

Graphical network of the top 20 diseases related to Heart Disease:



Diseases related to Heart Disease

Symptoms & Phenotypes for Heart Disease

UMLS symptoms related to Heart Disease:


tremor, angina pectoris, edema, chest pain, syncope, equilibration disorder

MGI Mouse Phenotypes related to Heart Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.65 ABL1 GATA4 MKKS MYH6 NKX2-5 NPPA
2 muscle MP:0005369 9.23 ABL1 GATA4 MYH6 NKX2-5 NPPA RYR2

Drugs & Therapeutics for Heart Disease

PubMedHealth treatment related to Heart Disease: 64

Although many children who have congenital heart defects don't need treatment, some do. Doctors repair congenital heart defects with catheter procedures or surgery.Sometimes doctors combine catheter and surgical procedures to repair complex heart defects, which may involve several kinds of defects.The treatment your child receives depends on the type and severity of his or her heart defect. Other factors include your child's age, size, and general health.Some children who have complex congenital heart defects may need several catheter or surgical procedures over a period of years, or they may need to take medicines for years.

Drugs for Heart Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1222)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 95635-55-5, 142387-99-3 56959
2
Alprostadil Approved, Investigational Phase 4,Phase 3,Not Applicable 745-65-3 5280723 149351
3
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
4
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
5
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 70789204 6442177
6
Cilostazol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 73963-72-1 2754
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 5284616 6436030
9
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 46507594 772
10
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2 128270-60-0 16129704
11
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 134523-00-5 60823
12
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 72956-09-3 2585
13
Clonidine Approved Phase 4,Not Applicable 4205-90-7 2803
14
Ropivacaine Approved Phase 4,Phase 2,Not Applicable 84057-95-4 175805 71273
15
Hydromorphone Approved, Illicit Phase 4,Phase 2 466-99-9 5284570
16
Sufentanil Approved, Investigational Phase 4,Phase 2,Not Applicable 56030-54-7 41693
17
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
18
Etomidate Approved Phase 4,Phase 2 33125-97-2 667484 36339
19
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 113775-47-6 5311068 68602
20
Sevoflurane Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 28523-86-6 5206
21
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
22
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
23
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274693-27-5 9871419
24
Nicorandil Approved, Investigational Phase 4,Not Applicable 65141-46-0 47528
25
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
26
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
27
Sulfasalazine Approved Phase 4 599-79-1 5359476 5353980
28
Adalimumab Approved Phase 4,Not Applicable 331731-18-1 16219006
29
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 11128-99-7, 68521-88-0, 4474-91-3 172198
30
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 137862-53-4 60846
31
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 98-92-0 936
32
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 32051
33
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
34
Verapamil Approved Phase 4,Phase 2,Phase 3,Not Applicable 52-53-9 2520
35
Sotalol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 959-24-0, 3930-20-9 5253
36
Amiodarone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1951-25-3 2157
37
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68-04-2
38
Cobalt Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 7440-48-4 104729
39
Chromium Approved Phase 4,Phase 3,Not Applicable 7440-47-3 27668
40
Pantoprazole Approved Phase 4,Phase 3 102625-70-7 4679
41
Esomeprazole Approved, Investigational Phase 4,Phase 2 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
42
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
43
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
44
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 57-83-0 5994
45
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 2,Phase 3 71-58-9
46
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
47
Exenatide Approved, Investigational Phase 4,Phase 3,Not Applicable 141758-74-9 15991534
48
Citalopram Approved Phase 4,Not Applicable 59729-33-8 2771
49
Ethinyl Estradiol Approved Phase 4,Phase 1,Not Applicable 57-63-6 5991
50
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0

Interventional clinical trials:

(show top 50) (show all 10084)
# Name Status NCT ID Phase Drugs
1 Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist Unknown status NCT00668824 Phase 4 Vasovist
2 Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
3 The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
4 Ranolazine for Improving Symptoms of Palpitations Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
5 PGE1 Improves Coronary Microcirculation Dysfunction in Patients With CAD and Diabetes Unknown status NCT03159559 Phase 4 Lipo-PGE1
6 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
7 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
8 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
9 Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
10 Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
11 Fluvastatin AmelIorates aTHerosclerosis Study Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
12 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Unknown status NCT01382277 Phase 4 Rosuvastatin
13 Diagnostic Benefits of HyperQTM vs. Conventional ECG Stress Test. Comparison of HyperQ vs. Stress ECG in Women Before Angiography Unknown status NCT00850486 Phase 4
14 Hemoderivative Imputable Complications in Initial Uncomplicated Heart Surgery Unknown status NCT01457586 Phase 4
15 Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
16 EPIC (Evaluating Perioperative Ischemia Reduction by Clonidine) Unknown status NCT00335582 Phase 4 clonidine hydrochloride
17 Randomized Anticoagulation Trial in Opcab (RATIO) Unknown status NCT02812355 Phase 4 Heparin
18 Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI Unknown status NCT03006835 Phase 4 Clopidogrel
19 Studies of Application of Combined General Anesthesia and Bilateral TPVB in OPCABG Unknown status NCT02727712 Phase 4 Anesthesia drugs during the surgery
20 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM) Unknown status NCT02044250 Phase 4 Clopidogrel;Aspirin
21 Relation Among Shear Stress Distribution, Stent Design, and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
22 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT Unknown status NCT01021930 Phase 4
23 Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
24 Test of Long-Term Safety and Efficacy of Sirolimus-Permanent-Polymer Eluting Stent (Cypher)- and Sirolimus-Polymer-free Eluting Stents (PPS/PFS) Assessed by Optical Coherence Tomography Unknown status NCT01260558 Phase 4
25 Test Safety and Efficacy of Zotarolimus- and Everolimus-Eluting Stents (ZES/EES) Assessed by Optical Coherence Tomography Unknown status NCT01230723 Phase 4
26 Test Efficacy of Biodegradable and Permanent Limus-Eluting Stents Unknown status NCT01068106 Phase 4
27 Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
28 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
29 Enteral Nutrition After Cardiovascular Surgery Unknown status NCT01432769 Phase 4
30 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
31 Metformin in Postmenopausal Women With Metabolic Syndrome Unknown status NCT01342744 Phase 4 Metformin;Placebo
32 Effect of Rosuvastatin Therapy on HDL2 Level Unknown status NCT02593487 Phase 4 Rosuvastatin 10mg/d group;Rosuvastatin 20mg/d group
33 The ABC Trial Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery? A Single Centre Pilot Study Unknown status NCT01623193 Phase 4
34 Comparison of Biolimus A9 and Everolimus Drug-Eluting Stents in Patients With ST Segment Elevation Myocardial Infarction Unknown status NCT00888758 Phase 4
35 Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
36 Revascularization in Heart Failure Trial – REHEAT 2 Unknown status NCT00388245 Phase 4
37 Effect of Ranolazine on Valvular Disease in Patients With Pacemakers Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
38 A Morbidity-Mortality and Remodeling Study With Valsartan Unknown status NCT00133328 Phase 4 valsartan
39 Patent Versus Generic Clopidogrel in Acute Coronary Syndrome Unknown status NCT02628587 Phase 4 Generic clopidogrel;Patent clopidogrel
40 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients Unknown status NCT01503671 Phase 4 Atorvastatin
41 Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP Unknown status NCT00584350 Phase 4
42 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
43 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4 pioglitazone
44 Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
45 Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias Unknown status NCT02303639 Phase 4 Antiarrhythmic drug therapy
46 Therapy With Verapamil or Carvedilol in Chronic Heart Failure Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
47 Rosuvastatin Effect on Telomere-telomerase System in ACS Unknown status NCT02299245 Phase 4 rosuvastatin
48 Does Sildenafil Protect Against Pulmonary Related Complications Following Cardiopulmonary Bypass? Unknown status NCT00350441 Phase 4 Sildenafil Citrate
49 Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
50 Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII Unknown status NCT01918150 Phase 4

Search NIH Clinical Center for Heart Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: heart diseases

Genetic Tests for Heart Disease

Genetic tests related to Heart Disease:

# Genetic test Affiliating Genes
1 Congenital Heart Disease 30
2 Congenital Heart Defects 30

Anatomical Context for Heart Disease

MalaCards organs/tissues related to Heart Disease:

42
Heart, Testes, Endothelial, Kidney, Lung, Brain, Bone

Publications for Heart Disease

Articles related to Heart Disease:

(show top 50) (show all 17552)
# Title Authors Year
1
Psychological traits, heart rate variability, and risk of coronary heart disease in healthy aging women - the Women's Health Initiative. ( 30688770 )
2019
2
Popeye's sign, heart disease, and amyloidosis. ( 30799016 )
2019
3
Depression and anxiety are associated with high health care utilization and mortality among adults with congenital heart disease. ( 30224258 )
2019
4
Elusive Taussig-Bing anomaly/aortic valve atresia: a rare case of congenital heart disease-correlation of fetal and neonatal echo images and direct anatomical photographs. ( 30600439 )
2019
5
Quantitative proteomics of changes in succinylated proteins expression profiling in left appendages tissue from valvular heart disease patients with atrial fibrillation. ( 31059701 )
2019
6
Circular RNA expression profiles of persistent atrial fibrillation in patients with rheumatic heart disease. ( 30587718 )
2019
7
Involvement of Apelin/APJ Axis in Thrombogenesis in Valve Heart Disease Patients with Atrial Fibrillation. ( 30518720 )
2019
8
Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study. ( 29986001 )
2019
9
What kills us and what moves us: A comparative discourse analysis of heart disease and breast cancer. ( 31069103 )
2019
10
Increased incidence of ischaemic heart disease and cerebrovascular disease in psoriasis patients with depression: a nationwide retrospective cohort study. ( 30977931 )
2019
11
Non-fasting triglyceride levels in the Korean population with and without ischemic heart disease and cerebrovascular disease. ( 29132199 )
2019
12
Clinical study of chlamydia pneumoniae infection in patients with coronary heart disease. ( 31088358 )
2019
13
Targeted next‑generation sequencing for research and diagnostics in congenital heart disease, and cleft lip and/or palate. ( 30896870 )
2019
14
Intake of 12 food groups and disability-adjusted life years from coronary heart disease, stroke, type 2 diabetes, and colorectal cancer in 16 European countries. ( 31030306 )
2019
15
Associations of calcium and dairy product intakes with all-cause, all-cancer, colorectal cancer, and coronary heart disease mortality among older women in the Iowa Women's Health Study. ( 30834851 )
2019
16
Incidental Diagnosis of Congenital Tracheal Stenosis in Children With Congenital Heart Disease Presenting for Cardiac Surgery. ( 29753667 )
2019
17
Cardiac Denial and Expectations Associated With Depression in Adults With Congenital Heart Disease. ( 30967286 )
2019
18
Clarifying the Concept of Depression in Women With Coronary Heart Disease. ( 30864985 )
2019
19
Effect of text messaging on depression in patients with coronary heart disease: a substudy analysis from the TEXT ME randomised controlled trial. ( 30787075 )
2019
20
Right-Sided Subcutaneous Implantable Cardioverter Defibrillator System Implantation in a Patient with Complex Congenital Heart Disease and Dextrocardia: A Case Report and Literature Review. ( 30867968 )
2019
21
Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. ( 30423457 )
2019
22
Maternal LINE-1 DNA Methylation and Congenital Heart Defects in Down Syndrome. ( 30787943 )
2019
23
Surgical Treatment for Congenital Heart Defects in Down Syndrome Patients. ( 30810666 )
2019
24
Right-sided endocarditis on Contegra tube in a complex cianotic congenital heart disease. ( 30972721 )
2019
25
Prosthetic pulmonary valve and conduit endocarditis in congenital heart disease. ( 30791694 )
2019
26
Effect of Congenital Heart Disease Status on Trends in Pediatric Infective Endocarditis Hospitalizations in the United States Between 2000 and 2012. ( 30415379 )
2019
27
Newborn Screening Pulse Oximetry to Detect Critical Congenital Heart Disease: A Follow-Up Survey of Current Practice at Army, Navy and Air Force Hospitals. ( 31090912 )
2019
28
Oxygen Saturation and Perfusion Index-Based Enhanced Critical Congenital Heart Disease Screening. ( 31003242 )
2019
29
Perfusion index cannot be currently recommended as an additional newborn screen for critical congenital heart disease: more data needed. ( 30971399 )
2019
30
FEATURES OF ENDOTHELIAL DYSFUNCTION IN ELDERLY PERSONS WITH CORONARY HEART DISEASE AND CONCOMITANT GASTROESOPHAGEAL REFLUX DISEASE. ( 30958293 )
2019
31
Should we start a nationwide screening program for critical congenital heart disease in Turkey? A pilot study on four centres with different altitudes. ( 30957737 )
2019
32
Brain and CSF Volumes in Fetuses and Neonates with Antenatal Diagnosis of Critical Congenital Heart Disease: A Longitudinal MRI Study. ( 30923087 )
2019
33
Actions in Support of Newborn Screening for Critical Congenital Heart Disease - United States, 2011-2018. ( 30730872 )
2019
34
Brain microstructural development in neonates with critical congenital heart disease: An atlas-based diffusion tensor imaging study. ( 30677732 )
2019
35
Impact of Family Socioeconomic Status on Health-Related Quality of Life in Children With Critical Congenital Heart Disease. ( 30563422 )
2019
36
Birth Location of Infants with Critical Congenital Heart Disease in California. ( 30415381 )
2019
37
Does pulsatility index add value to newborn pulse oximetry screening for critical congenital heart disease? ( 30413491 )
2019
38
Pulse oximetry screening for critical congenital heart disease: a comparative study of cohorts over 11 years ( 30332903 )
2019
39
Antenatal Detection of Treatable Critical Congenital Heart Disease Is Associated with Lower Morbidity and Mortality. ( 30292491 )
2019
40
The neonatal brain in critical congenital heart disease: Insights and future directions. ( 29787864 )
2019
41
The marker of adverse prognosis 1.5-anhydroglucitol in patients with coronary heart disease in the long-term period after planned myocardial revascularization. ( 31094476 )
2019
42
The "Heart Valve Clinic" Pathway for the Management of Frail Patients With Valvular Heart Disease: From "One for All" to "All for One". ( 31094730 )
2019
43
Egg consumption, cholesterol intake, and risk of incident stroke in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. ( 31095282 )
2019
44
Improving neurodevelopment in infants with complex congenital heart disease. ( 31099484 )
2019
45
Navigating the non-coding genome in heart development and Congenital Heart Disease. ( 31102825 )
2019
46
Circulating phylloquinone, inactive Matrix Gla protein and coronary heart disease risk: A two-sample Mendelian Randomization study. ( 31103344 )
2019
47
Task Sharing in the Diagnosis, Prevention, and Management of Rheumatic Heart Disease: A Systematic Review. ( 31103400 )
2019
48
Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review. ( 31104152 )
2019
49
Thoracic oncology and severe heart disease: pushing the limits! ( 31104369 )
2019
50
Surgical treatment of concomitant severe heart disease and lung cancer. ( 31104373 )
2019

Variations for Heart Disease

ClinVar genetic disease variations for Heart Disease:

6 (show top 50) (show all 76)
# Gene Variation Type Significance SNP ID Assembly Location
1 NKX2-5 NM_004387.3(NKX2-5): c.73C> T (p.Arg25Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs28936670 GRCh37 Chromosome 5, 172662014: 172662014
2 NKX2-5 NM_004387.3(NKX2-5): c.73C> T (p.Arg25Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs28936670 GRCh38 Chromosome 5, 173235011: 173235011
3 NKX2-5 NM_004387.3(NKX2-5): c.61G> C (p.Glu21Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs104893904 GRCh37 Chromosome 5, 172662026: 172662026
4 NKX2-5 NM_004387.3(NKX2-5): c.61G> C (p.Glu21Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs104893904 GRCh38 Chromosome 5, 173235023: 173235023
5 GATA4 NM_002052.4(GATA4): c.909+25G> A single nucleotide variant Conflicting interpretations of pathogenicity rs147860174 GRCh37 Chromosome 8, 11607770: 11607770
6 GATA4 NM_002052.4(GATA4): c.909+25G> A single nucleotide variant Conflicting interpretations of pathogenicity rs147860174 GRCh38 Chromosome 8, 11750261: 11750261
7 GATA4 NM_002052.4(GATA4): c.997+56C> A single nucleotide variant Conflicting interpretations of pathogenicity rs804280 GRCh37 Chromosome 8, 11612698: 11612698
8 GATA4 NM_002052.4(GATA4): c.997+56C> A single nucleotide variant Conflicting interpretations of pathogenicity rs804280 GRCh38 Chromosome 8, 11755189: 11755189
9 PTCH1 NM_000264.4(PTCH1): c.2945G> A (p.Arg982Gln) single nucleotide variant Uncertain significance rs145924695 GRCh37 Chromosome 9, 98220518: 98220518
10 PTCH1 NM_000264.4(PTCH1): c.2945G> A (p.Arg982Gln) single nucleotide variant Uncertain significance rs145924695 GRCh38 Chromosome 9, 95458236: 95458236
11 MYH6 NM_002471.3(MYH6): c.2575G> T (p.Gly859Trp) single nucleotide variant Uncertain significance rs369274077 GRCh37 Chromosome 14, 23863387: 23863387
12 MYH6 NM_002471.3(MYH6): c.2575G> T (p.Gly859Trp) single nucleotide variant Uncertain significance rs369274077 GRCh38 Chromosome 14, 23394178: 23394178
13 NKX2-5 NM_004387.3(NKX2-5): c.443C> A (p.Ala148Glu) single nucleotide variant Pathogenic rs864321649 GRCh38 Chromosome 5, 173233101: 173233101
14 NKX2-5 NM_004387.3(NKX2-5): c.443C> A (p.Ala148Glu) single nucleotide variant Pathogenic rs864321649 GRCh37 Chromosome 5, 172660104: 172660104
15 NKX2-5 NM_004387.3(NKX2-5): c.391G> A (p.Glu131Lys) single nucleotide variant Pathogenic rs864321648 GRCh38 Chromosome 5, 173233153: 173233153
16 NKX2-5 NM_004387.3(NKX2-5): c.391G> A (p.Glu131Lys) single nucleotide variant Pathogenic rs864321648 GRCh37 Chromosome 5, 172660156: 172660156
17 NKX2-5 NM_004387.3(NKX2-5): c.335-1G> T single nucleotide variant Pathogenic rs864321645 GRCh38 Chromosome 5, 173233210: 173233210
18 NKX2-5 NM_004387.3(NKX2-5): c.335-1G> T single nucleotide variant Pathogenic rs864321645 GRCh37 Chromosome 5, 172660213: 172660213
19 NKX2-5 NM_004387.3(NKX2-5): c.335-12G> A single nucleotide variant Uncertain significance rs864321646 GRCh38 Chromosome 5, 173233221: 173233221
20 NKX2-5 NM_004387.3(NKX2-5): c.335-12G> A single nucleotide variant Uncertain significance rs864321646 GRCh37 Chromosome 5, 172660224: 172660224
21 NKX2-5 NM_004387.3(NKX2-5): c.335-20G> A single nucleotide variant Uncertain significance rs864321647 GRCh38 Chromosome 5, 173233229: 173233229
22 NKX2-5 NM_004387.3(NKX2-5): c.335-20G> A single nucleotide variant Uncertain significance rs864321647 GRCh37 Chromosome 5, 172660232: 172660232
23 NKX2-5 NM_004387.3(NKX2-5): c.182C> G (p.Ala61Gly) single nucleotide variant Pathogenic rs864321650 GRCh38 Chromosome 5, 173234902: 173234902
24 NKX2-5 NM_004387.3(NKX2-5): c.182C> G (p.Ala61Gly) single nucleotide variant Pathogenic rs864321650 GRCh37 Chromosome 5, 172661905: 172661905
25 GATA4 NM_002052.4(GATA4): c.682T> A (p.Trp228Arg) single nucleotide variant Pathogenic rs864321702 GRCh37 Chromosome 8, 11606493: 11606493
26 GATA4 NM_002052.4(GATA4): c.23C> A (p.Ala8Asp) single nucleotide variant Pathogenic